Decipher识别临床有利中危前列腺癌中可能不适合主动监测的男性
本研究验证Decipher预测NCCN有利中危(F-IR)前列腺癌根治术(RP)后不良病理(AP)的能力,以更好筛选主动监测(AS)候选者。647例VL/LR或F-IR患者接受RP,Decipher为AP独立预测因子(每增加0.1单位OR=1.34,P=0.002),F-IR且Decipher低/中评分者AP风险与VL/LR无显著差异。结论认为NCCN风险分组异质性高,应替换为多变量风险分层,纳入Decipher可能有助于安全扩大AS使用。
要点
- Decipher是F-IR前列腺癌RP后不良病理的独立预测因子(每0.1单位OR=1.34,P=0.002)。
- F-IR且Decipher低/中评分者AP风险与VL/LR无显著差异。
- NCCN风险分组异质性高,应替换为多变量风险分层。
核心结论
- NCCN风险分组(包括F-IR)高度异质,应替换为多变量风险分层。
- 纳入Decipher可能有助于安全扩大该人群的AS使用。
研究设计与样本
- 从多机构前列腺癌活检数据库识别647例NCCN极低/低危(VL/LR)或F-IR前列腺癌患者,均接受RP并具有完整术后临床病理信息和Decipher基因组风险评分。
主要发现
- 220例NCCN F-IR患者中位年龄61岁(四分位距56-66),53%为CAPRA 0-2低危,47%为CAPRA 3-5中危。
- Decipher将79%、13%、8%的F-IR男性分别归为低、中、高风险,AP率分别为13%、10%、41%。
- Decipher是AP的独立预测因子,每增加0.1单位OR=1.34(P=0.002),校正CAPRA后仍显著。
- F-IR且Decipher低或中评分者与VL/LR相比AP风险无显著升高。
关键数值与推荐
- AP定义为分级分组3-5、pT3b或更高、或淋巴结侵犯。
- Decipher低、中、高风险组AP率分别为13%、10%、41%。
- Decipher每增加0.1单位OR=1.34(P=0.002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to validate Decipher to predict adverse pathology (AP) at radical prostatectomy (RP) in men with National Comprehensive Cancer Network (NCCN) favorable-intermediate risk (F-IR) prostate cancer (PCa), and to better select F-IR candidates for active surveillance (AS). METHODS: In all, 647 patients diagnosed with NCCN very low/low risk (VL/LR) or F-IR prostate cancer were identified from a multi-institutional PCa biopsy database; all underwent RP with complete postoperative clinicopathological information and Decipher genomic risk scores. The performance of all risk assessment tools was evaluated using logistic regression model for the endpoint of AP, defined as grade group 3-5, pT3b or higher, or lymph node invasion. RESULTS: The median age was 61 years (interquartile range 56-66) for 220 patients with NCCN F-IR disease, 53% classified as low-risk by Cancer of the Prostate Risk Assessment (CAPRA 0-2) and 47% as intermediate-risk (CAPRA 3-5). Decipher classified 79%, 13% and 8% of men as low-, intermediate- and high-risk with 13%, 10%, and 41% rate of AP, respectively. Decipher was an independent predictor of AP with an odds ratio of 1.34 per 0.1 unit increased (p value = 0.002) and remained significant when adjusting by CAPRA. Notably, F-IR with Decipher low or intermediate score did not associate with significantly higher odds of AP compared to VL/LR. CONCLUSIONS: NCCN risk groups, including F-IR, are highly heterogeneous and should be replaced with multivariable risk-stratification. In particular, incorporating Decipher may be useful for safely expanding the use of AS in this patient population.
引用
- Herlemann A, Huang HC, Alam R, et al. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer Prostatic Dis. 2019. PMID: 31455846. doi:10.1038/s41391-019-0167-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。